It was less than 12 months ago that Paul Hudson took the reins at the French drug giant Sanofi, promising to refocus the company on more innovative, and lucrative, new medicines. On Monday, he spoke with STAT to about the decision to purchase Principia Biopharma for $3.7 billion — as well as Sanofi’s overall strategy and its Covid-19 vaccine candidates.

The biggest near-term opportunity for Sanofi is in Dupixent, the drug for autoimmune disorders that Sanofi sells with Regeneron, the Tarrytown, N.Y., biotech firm. Sanofi has said sales could reach $10 billion annually.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy